Abstract
Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.
| Original language | English (US) |
|---|---|
| Journal | Journal of Hypertension |
| Volume | 20 |
| Issue number | SUPPL. 2 |
| DOIs | |
| State | Published - May 2002 |
Fingerprint
Keywords
- Cardiovascular risk
- Gender
- Hypertension
- Meta-analysis
- Randomized control trial
- Women
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
Cite this
Evidence-based medicine and treatment of hypertension in women : Results of trials. / Hayes, Sharonne N.
In: Journal of Hypertension, Vol. 20, No. SUPPL. 2, 05.2002.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence-based medicine and treatment of hypertension in women
T2 - Results of trials
AU - Hayes, Sharonne N.
PY - 2002/5
Y1 - 2002/5
N2 - Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.
AB - Purpose: The aim of this review is to summarize the evidence from randomized controlled trials and meta-analyses of hypertension treatment trials that included women in their study population and subsequent analyses. Results: Most early hypertension treatment trials did not include women in their study population, or did so in insufficient numbers to assess gender-specific outcomes. Women, particularly the elderly, were better represented in subsequent studies, but gender-specific results were not often reported and most trials were not designed or powered to detect gender differences in treatment responses and outcomes. In some studies where gender-specific results have been reported, gender differences have been observed, but the direction of the effect has generally been similar in men and women. Large meta-analyses of treatment trials have found similar relative risk reductions as a result of hypertension treatment, but lower absolute risk reductions in women compared to men. Absolute risk reductions are strongly related to baseline risk and have been demonstrated in virtually all subgroups of women except those with extremely low aggregate cardiovascular risk. While there are still limited data regarding treatment benefits for young women, no subset of women has been shown to experience net harm as a result of hypertension therapy. Conclusion: The design and implementation of future hypertension treatment trials should include the provision to assess gender-specific differences in treatment and outcomes.
KW - Cardiovascular risk
KW - Gender
KW - Hypertension
KW - Meta-analysis
KW - Randomized control trial
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=0036563334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036563334&partnerID=8YFLogxK
U2 - 10.1097/00004872-200212000-00001
DO - 10.1097/00004872-200212000-00001
M3 - Article
C2 - 12183852
AN - SCOPUS:0036563334
VL - 20
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - SUPPL. 2
ER -